Header Logo
Last Name

Dr Anna Vassall

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Vassall A, Siapka M, Foster N, Cunnama L, Ramma L, Fielding K, McCarthy K, Churchyard G, Grant A, Sinanovic E. Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. Lancet Glob Health. 2017 Jul; 5(7):e710-e719. PMID: 28619229.
      View in: PubMed
    2. Zwerling A, Gomez GB, Pennington J, Cobelens F, Vassall A, Dowdy DW. A simplified cost-effectiveness model to guide decision-making for shortened anti-tuberculosis treatment regimens. Int J Tuberc Lung Dis. 2016 Feb; 20(2):257-60. PMID: 26792481.
      View in: PubMed
    3. Trajman A, Bastos ML, Belo M, Calaça J, Gaspar J, Dos Santos AM, Dos Santos CM, Brito RT, Wells WA, Cobelens FG, Vassall A, Gomez GB. Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services. BMC Health Serv Res. 2016 Jan 22; 16:27. PMID: 26800677; PMCID: PMC4722708.
    4. Knight GM, Gomez GB, Dodd PJ, Dowdy D, Zwerling A, Wells WA, Cobelens F, Vassall A, White RG. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa. PLoS One. 2015; 10(12):e0145796. PMID: 26717007; PMCID: PMC4696677.
    5. Ramma L, Cox H, Wilkinson L, Foster N, Cunnama L, Vassall A, Sinanovic E. Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis. 2015 Dec; 19(12):1513-9. PMID: 26614194.
      View in: PubMed
    6. Kimani J, Warren CE, Abuya T, Ndwiga C, Mayhew S, Vassall A, Mutemwa R, Askew I. Use of HIV counseling and testing and family planning services among postpartum women in Kenya: a multicentre, non-randomised trial. BMC Womens Health. 2015 Nov 13; 15:104. PMID: 26563220; PMCID: PMC4643518.
    7. Remme M, Watts C, Heise L, Vassall A. Secondary schooling might be as good an HIV investment as male circumcision. Lancet Glob Health. 2015 Oct; 3(10):e591. PMID: 26385294.
      View in: PubMed
    8. Nabukenya-Mudiope MG, Kawuma HJ, Brouwer M, Mudiope P, Vassall A. Tuberculosis retreatment 'others' in comparison with classical retreatment cases; a retrospective cohort review. BMC Public Health. 2015 Sep 02; 15:840. PMID: 26330223; PMCID: PMC4556407.
    9. Laurence YV, Griffiths UK, Vassall A. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review. Pharmacoeconomics. 2015 Sep; 33(9):939-55. PMID: 25939501; PMCID: PMC4559093.
    10. Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, Erasmus LK, Ndjeka NO, Mvusi L, Vassall A, Sinanovic E, Cox HS, Dye C, Grant AD, Fielding KL. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health. 2015 Aug; 3(8):e450-e457. PMID: 26187490.
      View in: PubMed
    11. Obure CD, Sweeney S, Darsamo V, Michaels-Igbokwe C, Guinness L, Terris-Prestholt F, Muketo E, Nhlabatsi Z. The Costs of Delivering Integrated HIV and Sexual Reproductive Health Services in Limited Resource Settings. PLoS One. 2015; 10(5):e0124476. PMID: 25933414; PMCID: PMC4416893.
    12. Källander K, Strachan D, Soremekun S, Hill Z, Lingam R, Tibenderana J, Kasteng F, Vassall A, Meek S, Kirkwood B. Evaluating the effect of innovative motivation and supervision approaches on community health worker performance and retention in Uganda and Mozambique: study protocol for a randomised controlled trial. Trials. 2015 Apr 12; 16:157. PMID: 25873093; PMCID: PMC4432981.
    13. Lépine A, Vassall A, Chandrashekar S. The determinants of technical efficiency of a large scale HIV prevention project: application of the DEA double bootstrap using panel data from the Indian Avahan. Cost Eff Resour Alloc. 2015; 13:5. PMID: 25861248; PMCID: PMC4389319.
    14. Fielding KL, Charalambous S, Hoffmann CJ, Johnson S, Tlali M, Dorman SE, Vassall A, Churchyard GJ, Grant AD. Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. Trials. 2015 Mar 28; 16:125. PMID: 25872501; PMCID: PMC4394596.
    15. Settumba SN, Sweeney S, Seeley J, Biraro S, Mutungi G, Munderi P, Grosskurth H, Vassall A. The health system burden of chronic disease care: an estimation of provider costs of selected chronic diseases in Uganda. Trop Med Int Health. 2015 Jun; 20(6):781-90. PMID: 25707376; PMCID: PMC4973817.
    16. Lépine A, Vassall A, Chandrashekar S, Blanc E, Le Nestour A. Estimating unbiased economies of scale of HIV prevention projects: a case study of Avahan. Soc Sci Med. 2015 Apr; 131:164-72. PMID: 25779621.
      View in: PubMed
    17. Sinanovic E, Ramma L, Vassall A, Azevedo V, Wilkinson L, Ndjeka N, McCarthy K, Churchyard G, Cox H. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis. 2015 Feb; 19(2):172-8. PMID: 25574915; PMCID: PMC4447891.
    18. Foster N, Vassall A, Cleary S, Cunnama L, Churchyard G, Sinanovic E. The economic burden of TB diagnosis and treatment in South Africa. Soc Sci Med. 2015 Apr; 130:42-50. PMID: 25681713.
      View in: PubMed
    19. Remme M, Siapka M, Vassall A, Heise L, Jacobi J, Ahumada C, Gay J, Watts C. The cost and cost-effectiveness of gender-responsive interventions for HIV: a systematic review. J Int AIDS Soc. 2014; 17:19228. PMID: 25373519; PMCID: PMC4221500.
    20. Zwerling A, White RG, Vassall A, Cohen T, Dowdy DW, Houben RM. Modeling of novel diagnostic strategies for active tuberculosis - a systematic review: current practices and recommendations. PLoS One. 2014; 9(10):e110558. PMID: 25340701; PMCID: PMC4207742.
    21. Vassall A, Chandrashekar S, Pickles M, Beattie TS, Shetty G, Bhattacharjee P, Boily MC, Vickerman P, Bradley J, Alary M, Moses S. Community mobilisation and empowerment interventions as part of HIV prevention for female sex workers in Southern India: a cost-effectiveness analysis. PLoS One. 2014; 9(10):e110562. PMID: 25333501; PMCID: PMC4204894.
    22. Kufa T, Hippner P, Charalambous S, Kielmann K, Vassall A, Churchyard GJ, Grant AD, Fielding KL. A cluster randomised trial to evaluate the effect of optimising TB/HIV integration on patient level outcomes: the "merge" trial protocol. Contemp Clin Trials. 2014 Nov; 39(2):280-7. PMID: 25315287.
      View in: PubMed
    23. Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, Glaziou P, White RG. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014 Oct 28; 111(43):15520-5. PMID: 25288770; PMCID: PMC4217399.
    24. Panovska-Griffiths J, Vassall A, Prudden HJ, Lépine A, Boily MC, Chandrashekar S, Mitchell KM, Beattie TS, Alary M, Martin NK, Vickerman P. Optimal allocation of resources in female sex worker targeted HIV prevention interventions: model insights from Avahan in South India. PLoS One. 2014; 9(10):e107066. PMID: 25271808; PMCID: PMC4182672.
    25. Chandrashekar S, Guinness L, Pickles M, Shetty GY, Alary M, Vickerman P. The costs of scaling up HIV prevention for high risk groups: lessons learned from the Avahan Programme in India. PLoS One. 2014; 9(9):e106582. PMID: 25203052; PMCID: PMC4159262.
    26. Dowdy DW, Houben R, Cohen T, Pai M, Cobelens F, Vassall A, Menzies NA, Gomez GB, Langley I, Squire SB, White R. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. Int J Tuberc Lung Dis. 2014 Sep; 18(9):1012-8. PMID: 25189546; PMCID: PMC4436823.
    27. Vassall A, Pickles M, Chandrashekar S, Boily MC, Shetty G, Guinness L, Lowndes CM, Bradley J, Moses S, Alary M. Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India. Lancet Glob Health. 2014 Sep; 2(9):e531-e540. PMID: 25304420.
      View in: PubMed
    28. Sweeney S, Obure CD, Terris-Prestholt F, Darsamo V, Michaels-Igbokwe C, Muketo E, Nhlabatsi Z, Warren C, Mayhew S, Watts C, Vassall A. The impact of HIV/SRH service integration on workload: analysis from the Integra Initiative in two African settings. Hum Resour Health. 2014 Aug 07; 12:42. PMID: 25103923; PMCID: PMC4130428.
    29. Houben RM, Dowdy DW, Vassall A, Cohen T, Nicol MP, Granich RM, Shea JE, Eckhoff P, Dye C, Kimerling ME, White RG. How can mathematical models advance tuberculosis control in high HIV prevalence settings? Int J Tuberc Lung Dis. 2014 May; 18(5):509-14. PMID: 24903784; PMCID: PMC4436821.
    30. Siapka M, Remme M, Obure CD, Maier CB, Dehne KL, Vassall A. Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries. Bull World Health Organ. 2014 Jul 01; 92(7):499-511AD. PMID: 25110375; PMCID: PMC4121865.
    31. Vassall A, Shotton J, Reshetnyk OK, Hasanaj-Goossens L, Weil O, Vohra J, Timmermans N, Vinyals L, Andre F. Tracking aid flows for development assistance for health. Glob Health Action. 2014; 7:23510. PMID: 24560260; PMCID: PMC3925818.
    32. Remme M, Vassall A, Lutz B, Luna J, Watts C. Financing structural interventions: going beyond HIV-only value for money assessments. AIDS. 2014 Jan 28; 28(3):425-34. PMID: 24670525.
      View in: PubMed
    33. van't Hoog AH, Cobelens F, Vassall A, van Kampen S, Dorman SE, Alland D, Ellner J. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysis. PLoS One. 2013; 8(12):e82786. PMID: 24367555; PMCID: PMC3867409.
    34. Vassall A, Remme M, Watts C, Hallett T, Siapka M, Vickerman P, Terris-Prestholt F, Haacker M, Heise L, Haines A, Atun R, Piot P. Financing essential HIV services: a new economic agenda. PLoS Med. 2013 Dec; 10(12):e1001567. PMID: 24358028; PMCID: PMC3866083.
    35. Vassall A, Remme M. Financing tuberculosis control: promising trends and remaining challenges. Lancet Glob Health. 2013 Aug; 1(2):e62-e63. PMID: 25104150.
      View in: PubMed
    36. Boily MC, Pickles M, Lowndes CM, Ramesh BM, Washington R, Moses S, Deering KN, Mitchell KM, Reza-Paul S, Blanchard J, Vassall A, Alary M, Vickerman P. Positive impact of a large-scale HIV prevention programme among female sex workers and clients in South India. AIDS. 2013 Jun 01; 27(9):1449-60. PMID: 23462221; PMCID: PMC3678895.
    37. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013; 10(3):e1001401. PMID: 23554579; PMCID: PMC3595225.
    38. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis. Eur Respir J. 2013 Sep; 42(3):708-20. PMID: 23258774.
      View in: PubMed
    39. Warren CE, Mayhew SH, Vassall A, Kimani JK, Church K, Obure CD, du-Preez NF, Abuya T, Mutemwa R, Colombini M, Birdthistle I, Askew I, Watts C. Study protocol for the Integra Initiative to assess the benefits and costs of integrating sexual and reproductive health and HIV services in Kenya and Swaziland. BMC Public Health. 2012 Nov 13; 12:973. PMID: 23148456; PMCID: PMC3529107.
    40. Kranzer K, Lawn SD, Meyer-Rath G, Vassall A, Raditlhalo E, Govindasamy D, van Schaik N, Wood R, Bekker LG. Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study. PLoS Med. 2012; 9(8):e1001281. PMID: 22879816; PMCID: PMC3413719.
    41. Obure CD, Vassall A, Michaels C, Terris-Prestholt F, Mayhew S, Stackpool-Moore L, Warren C. Optimising the cost and delivery of HIV counselling and testing services in Kenya and Swaziland. Sex Transm Infect. 2012 Nov; 88(7):498-503. PMID: 22859498; PMCID: PMC3595498.
    42. Dowdy D, Vassall A, Cobelens F. Tuberculosis control in crisis: economic honesty and comparative effectiveness. Int J Tuberc Lung Dis. 2012 Aug; 16(8):1131-2. PMID: 22762428.
      View in: PubMed
    43. Remme M, Vassall A, Lutz B, Watts C. Paying girls to stay in school: a good return on HIV investment? Lancet. 2012 Jun 09; 379(9832):2150. PMID: 22682463.
      View in: PubMed
    44. Chandrashekar S, Vassall A, Reddy B, Shetty G, Vickerman P, Alary M. The costs of HIV prevention for different target populations in Mumbai, Thane and Bangalore. BMC Public Health. 2011 Dec 29; 11 Suppl 6:S7. PMID: 22375837; PMCID: PMC3287560.
    45. Sweeney S, Obure CD, Maier CB, Greener R, Dehne K, Vassall A. Costs and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience. Sex Transm Infect. 2012 Mar; 88(2):85-99. PMID: 22158934.
      View in: PubMed
    46. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, Davis JL, Whitelaw A, Nicol MP, Gler MT, Khaliqov A, Zamudio C, Perkins MD, Boehme CC, Cobelens F. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011 Nov; 8(11):e1001120. PMID: 22087078; PMCID: PMC3210757.
    47. Martin NK, Pitcher AB, Vickerman P, Vassall A, Hickman M. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One. 2011; 6(8):e22309. PMID: 21853030; PMCID: PMC3154900.
    48. Vassall A, Seme A, Compernolle P, Meheus F. Patient costs of accessing collaborative tuberculosis and human immunodeficiency virus interventions in Ethiopia. Int J Tuberc Lung Dis. 2010 May; 14(5):604-10. PMID: 20392354.
      View in: PubMed
    49. Vassall A, Chechulin Y, Raykhert I, Osalenko N, Svetlichnaya S, Kovalyova A, van der Werf MJ, Turchenko LV, Hasker E, Miskinis K, Veen J, Zaleskis R. Reforming tuberculosis control in Ukraine: results of pilot projects and implications for the national scale-up of DOTS. Health Policy Plan. 2009 Jan; 24(1):55-62. PMID: 19056804.
      View in: PubMed
    50. Acuna-Villaorduna C, Vassall A, Henostroza G, Seas C, Guerra H, Vasquez L, Morcillo N, Saravia J, O'Brien R, Perkins MD, Cunningham J, Llanos-Zavalaga L, Gotuzzo E. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis. 2008 Aug 15; 47(4):487-95. PMID: 18636955.
      View in: PubMed
    51. van der Werf MJ, Chechulin Y, Yegorova OB, Marcinuk T, Stopolyanskiy A, Voloschuk V, Zlobinec M, Vassall A, Veen J, Hasker E, Turchenko LV. Health care seeking behaviour for tuberculosis symptoms in Kiev City, Ukraine. Int J Tuberc Lung Dis. 2006 Apr; 10(4):390-5. PMID: 16602402.
      View in: PubMed
    52. Vassall A, Compernolle P. Estimating the resource needs of scaling-up HIV/AIDS and tuberculosis interventions in sub-Saharan Africa: a systematic review for national policy makers and planners. Health Policy. 2006 Nov; 79(1):1-15. PMID: 16388874.
      View in: PubMed
    53. Vassall A, Bagdadi S, Bashour H, Zaher H, Maaren PV. Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria. Int J Tuberc Lung Dis. 2002 Dec; 6(12):1083-90. PMID: 12546116.
      View in: PubMed
    Vassall's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description